Sensei Biotherapeutics, Inc. (SNSE) Q3 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Your conference call should begin momentarily. Thank you. Thank you. Good afternoon. My name is Sally, and I'm the facilitator today. At this time, I would like to welcome everyone to the Sensei Biopharmaceutical Virtual Vista Science Symposium. All lines have been placed on mute. After Sensei's presentation, there will be a question and answer period. To ask a question during that time, please press star 1 on your telephones. If you'd like to withdraw your question, please press the pound key. I would now like to turn the conference over to your host, Mr. Shellaby. You may begin. Thank you, operator, and welcome everybody to our VISTA Science Symposium. We're really looking forward to today's meeting. We think it's a great nexus between deep immunology and biopharma drug development, and great timing coming on the heels of the CITSE annual meeting, where we presented some new data We're really, just a reminder before we get started, that we are a publicly traded company, and we may be making forward-looking statements today. I want to review the agenda with you. I'm going to make some opening remarks regarding our TMAB platform and mission. And then we'll be joined by Professor Robert Schreiber, a professor at the Washington University School of Medicine and a member of our scientific advisory board. We'll then turn it over to Dr. Robert Pierce, our Chief Scientific Officer, and Edward Vonderhorst will be available for question and answers. Edward Vonderhorst is our Senior Vice President of TMAB Antibody Development. Together this team has vast experience in VISTA biology and antibody development, and we're really excited to share our program with you today, and also what we've learned along the way. So just as we move forward, I want to share with you what the miss...